Processing the results of the first-ever prenatal test for cystic fibrosis will soon be the responsibility of a noted Grand Rapids molecular medicine research lab. The lab's parent company says the test will hit the market in the next few months.
According to excerpts from the story:
Sequenom Inc. plans to launch a new prenatal test for cystic fibrosis within the next few months, and the results will be processed by the company’s Center for Molecular Medicine in Grand Rapids, the CEO said Thursday. The cystic fibrosis test is the first of the California company’s three prenatal molecular diagnostic tests slated for launch following an April announcement that its widely anticipated Down syndrome test would be delayed by mishandling of test data.
“Our sales force plans to introduce this product in 18 metropolitan markets in the U.S. and it will be our first product launched by our CLIA laboratory, SCMM, into the clinical testing market,” CEO Harry Stylli told analysts in a quarterly earnings conference call. Stylli said the cystic fibrosis screening test, entering a $300 million market, is expected to be joined by a Rhesus D test and a gender test by the first quarter of 2010.
Read the complete story
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.